Evidence map›Paper›PMID 24434899›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2014

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.

Cecilia Lezcano, Chung-Wei Lee, Allison R Larson, Alexander M Menzies, Richard F Kefford, John F Thompson, Martin C Mihm, Shuji Ogino, Georgina V Long, Richard A Scolyer and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. The importance of being CAFs (in cancer resistance to targeted therapies).Journal of experimental & clinical cancer research : CR · 2022
    Review
  3. Article
  4. HGF/c-MET Signaling in Melanocytes and Melanoma.International journal of molecular sciences · 2018
    Review
  5. Article
  6. Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
  7. Article
  8. Nestin depletion induces melanoma matrix metalloproteinases and invasion.Laboratory investigation; a journal of technical methods and pathology · 2014
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Cecilia Lezcano1] Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
Chung-Wei Lee1] Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
Allison R Larson1] Harvard Medical School, Boston, MA, USA [2] Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
Alexander M Menzies1] Melanoma Institute Australia, Sydney, NSW, Australia [2] The University of Sydney, Camperdown, NSW, Australia.
Richard F Kefford1] Melanoma Institute Australia, Sydney, NSW, Australia [2] The University of Sydney, Camperdown, NSW, Australia [3] Westmead Institute for Cancer Research, NSW, Sydney, Australia.
John F Thompson1] Melanoma Institute Australia, Sydney, NSW, Australia [2] The University of Sydney, Camperdown, NSW, Australia [3] Mater Hospital, Sydney, NSW, Australia [4] Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Martin C Mihm1] Harvard Medical School, Boston, MA, USA [2] Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
Shuji Ogino1] Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA [3] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [4] Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
Georgina V Long1] Melanoma Institute Australia, Sydney, NSW, Australia [2] The University of Sydney, Camperdown, NSW, Australia [3] Westmead Institute for Cancer Research, NSW, Sydney, Australia.
Richard A Scolyer1] Melanoma Institute Australia, Sydney, NSW, Australia [2] The University of Sydney, Camperdown, NSW, Australia [3] Royal Prince Alfred Hospital, Sydney, NSW, Australia.
George F Murphy1] Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
Brigham and Women's Hospital · USMelanoma Institute Australia · AUHarvard University · USUniversity of Sydney · AUDana-Farber Cancer Institute · US

Funding

Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities forP50CA093683 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KUPPER, THOMAS S. · 2001 to 2012
$25.8M
VASCULAR, PULMONARY AND RENAL INJURYT32HL007627 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GIMBRONE, MICHAEL A, MITCHELL, RICHARD N · 1985 to 2019
$12.7M
Immunology of human malignant melanoma initiating cellsR01CA158467 · NCI · BOSTON CHILDREN'S HOSPITAL · PI FRANK, MARKUS H., HODI, FRANK S · 2012 to 2016
$1.9M
Melanoma Stem Cells, Vasculogenesis and Neoplastic ProgressionR01CA138231 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI FRANK, MARKUS H. · 2008 to 2012
$1.7M
NCI NIH HHS NIH-P50 CA93683NCI NIH HHS P50 CA093683NCI NIH HHS R01 CA138231NCI NIH HHS R01 CA158467NCI NIH HHS R01 CA158467-02NHLBI NIH HHS T32 HL007627
6 · The paper itself

Abstract

Of more than 150 000 published studies evaluating new biomarkers, fewer than 100 biomarkers have been implemented for patient care. One reason for this is lack of rigorous testing by the medical community to validate claims for biomarker clinical relevance, and potential reluctance to publish negative results when confirmation is not obtained. Here we sought to determine the utility and reproducibility of immunohistochemical detection of hepatocyte growth factor (HGF) in melanoma tissue, an approach of potential assistance in defining patients with innate resistance to BRAF inhibitor therapy. To this end, a published and a revised method that retained sensitivity but with greater specificity for HGF detection, were evaluated in cells known to endogenously express HGF, and in models where HGF is upregulated via cytokine induction and via overexpression by gene transfection. Consequent patient evaluation in collaboration with the Melanoma Institute Australia of a cohort of 41 melanoma specimens with extensive clinical annotation failed to validate HGF immunohistochemistry as a predictor of response to BRAF inhibitors. Targeted therapies for advanced melanoma and other cancers show great promise, and rigorous validation studies are thus indicated for approaches that seek to personalize such therapies to maximize therapeutic efficacy.

Indexed as

Antineoplastic AgentsBiomarkers, TumorBlotting, WesternCell LineFibroblastsGene ExpressionHepatocyte Growth FactorHumansImidazolesImmunohistochemistryIndolesMelanomaOximesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafReal-Time Polymerase Chain ReactionAntineoplastic AgentsBiomarkers, TumordabrafenibHepatocyte Growth FactorImidazolesIndolesOximesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRNA, MessengerSulfonamidesVemurafenib

Identifiers

PMID24434899
PMCPMC4107197
OpenAlexW2156909232

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.